New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
08:18 EDTPCYCPharmacyclics reports sNDA for Imbruvica accepted, priority review granted
Pharmacyclics announced that the FDA has accepted for filing its suplemental new drug application to support the review of Imbruvica in the treatment of patients with CLL and SLL who have received at least one prior therapy for a full approval. The target PDUFA date by which the FDA is planning to finalize the review of this application is October 7.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
16:02 EDTPCYCPharmacyclics, Server agree to end pan-HDAC inhibitor collaboration
Pharmacyclics and Servier announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat, thereby returning global development and commercialization rights to Pharmacyclics. A provisional patent application for abexinostat tosylate was filed with the U.S. Patent and Trademark Office in 2013 and, if issued, would extend patent protection until 2034. Pharmacyclics will evaluate the full opportunity that the compound may afford, and plans to provide an update on this program in mid 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use